Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 387, Issue 7, 2014, Pages 691-695

  Muhl, Daniela ^a   Kathmann, Markus ^b   Hoyer, Carolin ^c   Kranaster, Laura ^c   Hellmich, Martin ^a   Gerth, Christoph W ^a   Faulhaber, Johannes ^a   Schlicker, Eberhard ^b   Leweke, F Markus ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anandamide; Cannabis abuse; Smokers

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; MESSENGER RNA; AMIDE; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANNABIS ADDICTION; CANNABIS SMOKING; CANNABIS USE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GENE EXPRESSION; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; TANDEM MASS SPECTROMETRY; BLOOD; GENETICS; METABOLISM; MONONUCLEAR CELL; YOUNG ADULT;

ADULT; ARACHIDONIC ACIDS; ENDOCANNABINOIDS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MARIJUANA ABUSE; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; YOUNG ADULT;

EID: 84904088512     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-014-0984-2     Document Type: Article

References (20)

1. Blankman JL, Cravatt BF (2013) Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65:849-871
2. El-Gohary M, Eid MA (2004) Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol 23:149-156 (Pubitemid 38499892)
3. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61
4. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108-2114 (Pubitemid 39486563)
5. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327-360
6. Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374:1383-1391
7. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202 (Pubitemid 34575709)
8. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665-1669 (Pubitemid 29354290)
9. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden B, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D (2007) Anandamide levels in cerebrospinal fluid of firstepisode schizophrenic patients: impact of cannabis use. Schizophr Res 94:29-36 (Pubitemid 47031599)
10. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94
11. Lohse MJ (1993) Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta 1179:171-188
12. Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21-47
13. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319-328 (Pubitemid 47094993)
14. Morgan CJA, Page E, Schaefer C, Chatten K, Manocha A, Gulati S, Curran HV, Brandner B, Leweke FM (2013) Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Brit J Psychiatry 202:381-382
15. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW (2002) Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol 127:169-176 (Pubitemid 34603588)
16. Piomelli D (2014) More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology 76:228-234
17. Rom S, Persidsky Y (2013) Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol 8:608-620
18. 9- tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Mol Brain Res 46:100-108
19. Rotter A, Bayerlein K, Hansbauer M, Weiland J, Sperling W, Kornhuber J, Biermann T (2013) CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence. Eur Addict Res 19:13-20
20. Schreiber D, Harlfinger S, Nolden BM, Gerth CW, Jaehde U, Schömig E, Klosterkötter J, Giuffrida A, Astarita G, Piomelli D, Leweke FM (2007) Determination of anandamide and other fatty acid ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem 361:162-168 (Pubitemid 46135393)